Exactly my thoughts.

First 90 Last

Share
Profile

Follow
omaz

650 Posts.

181

25/06/20

15:07

Post #: 45449605
Share

Originally posted by Galilee13: ↑

I don't believe in this manipulation theory.

To me it's a simply case of over promise and failure to delivery. Yacov and Brendan have spent every last bit of credibility over the last 3 years with a lot of fluffy feel good announcements, with little or no follow up and thus no accountability.

They obviously took a huge punt on China which didn't work out. While waiting for China they didn't focus enough on Europe or the US.

The company announced many impressive MOUs in the hundreds of millions. None of which have amounted to anything. Yacov even set his initial performance shares based on sales and EBIT in the tens of millions.

This set the market expectation that these were the level of sales deals to expect into the future.

So, the prizma received CE mark in Sept 2017. It has taken almost 3 years to receive the first purchase order. And wait for it.... for 1000 units or about $100k. Yes it's a start and I'm happy with it, but it's not in the same league has the numbers the company has pumped up in the past. In other words it's has failed the market's expectations.

US IDTF business has been all acquired revenue and there is little evidence to suggest the company has managed to grow the revenue at all. However, they are must have infrastructure assets in order to roll out the prizma and patch in due course.

Patch received CE mark in nov 2017. Nothing further here.

Prizma receives FDA (prescription only) in sept 2017. Did absolutely nothing with it until OTC was received in April this year. Now, I'm super excited with the deal with Live Care USA. This will be a company maker and I can't wait for them to start advertising. My gut feeling is Yacov and Peri are good mates and they won't start advertising until after the AGM.

Failed listings in HK and Nasdaq.

An almost doubling of shares on issue over the past 12 months. Yes the balance sheet is cleaned up and a real positive. The real killer was Yacov selling stock to meet a quasi margin call and then we have these outrageous performance shares. These two things alone have completely killed all the good work the company has done this year in terms of approvals and distribution agreements.

I think the market believes in the story, the products and the business model. But there is a huge questions mark over Yacov, management, ability to execute and how they continue to treat shareholders.

I could go on and on. But you get my point.

Expand

Exactly my thoughts.

GMV Price at posting: 4.6¢ Sentiment: Hold Disclosure: Held
5 Upvote

0 Great analysis

Reply